Triple cardiovascular disease detection with an artificial intelligence-enabled stethoscope (TRICORDER) in the UK: a cluster-randomised controlled implementation trial

COMMENTED

Cardiovascular Risk and Diseases

Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Lancet Diabetes Endocrinol

Hauge JW, Borgeraas H, Birkeland KI, Johnson LK, Hertel JK, Hagen M, Gulseth HL, Lindberg M, Lorentzen J, Seip B, Kolotkin RL, Svanevik M, Valderhaug TG, Sandbu R, Hjelmesæth J, Hofsø D

doi: 10.1016/S2213-8587(24)00396-6

Further Publications

Detecting Transthyretin Cardiac Amyloidosis With Artificial Intelligence: A Nonrandomized Clinical Trial

JAMA Cardiol

Jain SS, Sun T, Pierson E, Roedan Oliver F, Malta P, Castillo M, Wan N, Alishetti S, Hartman H, Finer J, Brown KL, Ramlall V, Tatonetti N, Elhadad N, Rodriguez F, Witteles R, Goyal P, Homma S, Einstein AJ, Maurer MS, Elias P, Poterucha TJ

doi: 10.1001/jamacardio.2025.4591

Heart, Artery and Coronary Diseases

Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in patients with intermittent claudication (SWEDEPAD 2): a multicentre, participant-masked, registry-based, randomised controlled trial

Lancet

Nordanstig J, James S, Andersson M, Andersson M, Delle M, Engström J, Fransson T, Gillgren P, Hilbertson A, Hörer TM, Jacobsson E, Kragsterman B, Lindbäck J, Lindgren H, Ludwigs K, Mellander S, Nelzén O, Olin R, Sigvant B, Skoog P, Starck J, Tegler G, Thorbjørnsen K, Truedson M, Wahlgren CM, Wallinder J, Öjersjö A, Falkenberg M, SWEDEPAD trial investigators

doi: 10.1016/S0140-6736(25)01584-3

Cardiovascular Risk and Diseases

Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials

Lancet

Pyne L, Rossignol P, Giles C, Junek M, Mark PB, Gallagher M, de Zoysa JR, Devereaux PJ, Walsh M

doi: 10.1016/S0140-6736(25)01153-5

Cardiovascular Risk and Diseases

Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial

JAMA Cardiol

Nicholls SJ, Ryan DH, Deanfield J, Ferreira D, Lang CC, Lincoff AM, Lingvay I, Lübker C, Terns PP, Rasmussen S, Stensen S, Weeke PE, Kahn SE, SELECT Trial Investigators

doi: 10.1001/jamacardio.2025.4824

Hypertension

Leveraging Preexisting Cardiovascular Data to Improve the Detection and Treatment of Hypertension: The NOTIFY-LVH Randomized Clinical Trial

JAMA Cardiol

Berman AN, Hidrue MK, Ginder C, Shirkey L, Kwatra J, O'Kelly AC, Murphy SP, Searl Como JM, Daly D, Sun YP, Curry WT, Del Carmen MG, Blankstein R, Dodson JA, Morrow DA, Scirica BM, Choudhry NK, Januzzi JL Jr, Wasfy JH

doi: 10.1001/jamacardio.2025.0871

Heart Failure

Primary care Adherence To Heart failure guidelines in post-Discharge, Evaluation & Routine management (PATHFINDER): a randomised controlled trial

ESC Heart Fail

Dai L, Dorje T, Gootjes J, Shah A, Dembo L, Hillis GS, Jacques A, Chih HJ, Rankin J, Atherton JJ, Robinson S, Reid CM, Maiorana A

doi: 10.1093/eschf/xvag061

Heart, Artery and Coronary DiseasesTherapy and Intervention

ACURATE neo2 valve versus commercially available transcatheter heart valves in patients with severe aortic stenosis (ACURATE IDE): a multicentre, randomised, controlled, non-inferiority trial

Lancet

Makkar RR, Ramana RK, Gnall E, Ramlawi B, Cheng W, Diamantouros P, Potluri S, Kleinman N, Gupta A, Chakravarty T, Samy S, Rassi A, Rajagopal V, Yakubov S, Sorajja P, Patel D, Garcia S, Yadav P, Thourani V, Wang J, Rinaldi M, Kapadia S, Waksman R, Webb J, Ren CB, Gregson J, Modolo R, Sathananthan J, Reardon MJ, ACURATE IDE study investigators

doi: 10.1016/S0140-6736(25)00319-8

Cardiovascular Risk and Diseases

AHA PREVENT Equations and Lipoprotein(a) for Cardiovascular Disease Risk : Insights From MESA and the UK Biobank

JAMA Cardiol

Bhatia HS, Ambrosio M, Razavi AC, Alebna PL, Yeang C, Spitz JA, Patel J, Tsai MY, Sperling L, Shapiro MD, Tsimikas S, Mehta A

doi: 10.1001/jamacardio.2025.1603

Related content

Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial

Detecting Transthyretin Cardiac Amyloidosis With Artificial Intelligence: A Nonrandomized Clinical Trial

Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in patients with intermittent claudication (SWEDEPAD 2): a multicentre, participant-masked, registry-based, randomised controlled trial

Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials

Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial

Leveraging Preexisting Cardiovascular Data to Improve the Detection and Treatment of Hypertension: The NOTIFY-LVH Randomized Clinical Trial

Primary care Adherence To Heart failure guidelines in post-Discharge, Evaluation & Routine management (PATHFINDER): a randomised controlled trial

ACURATE neo2 valve versus commercially available transcatheter heart valves in patients with severe aortic stenosis (ACURATE IDE): a multicentre, randomised, controlled, non-inferiority trial

AHA PREVENT Equations and Lipoprotein(a) for Cardiovascular Disease Risk : Insights From MESA and the UK Biobank